Article Figures & Data
Figures
- Fig 1.
Screenshots from 3D Slicer showing an outline of the masks (white arrows) delineating a metastatic lesion in the right frontal lobe from breast cancer on an axial plane DCE-MRI. (A) shows the metastasis as well as the 2 × 2 × 1 voxel control mask in the superior sagittal sinus, while (B) shows the same lesion mask two slices inferiorly. Also shown is the arterial input function of the contrast history at a single pixel (lower part).
- Fig 2.
The Kaplan-Meier curve of progression-free survival for all LITT cases (n = 33).
- Fig 3.
Immediate postoperative T1-weighted postcontrast MRIs showing a region of T1 hyperintensity (white arrows) consistent with treatment change within the ablation zone in a patient with a short PFS (86 days from LITT, iAUC60 = 1.81) (A) and good long-term control (no recurrence 329 days from LITT, iAUC60 = 1.29) (B). This patient illustrates that T1-weighted postcontrast MR imaging is not sufficient for distinguishing completely ablated lesions versus partially ablated lesions shortly after thermal ablation and supports the need for DCE-MR imaging in this setting.
- Fig 4.
Scatterplot with the line of best fit for iAUC60 values from postoperative DCE-MR imaging (r = −0.64, P = .03) (A) and DCE-MR imaging at 1-month follow-up with the line of best fit drawn with the outlier (marked by x) excluded (r = −0.46, P = .05) (B). The correlation of PFS and ΔiAUC60 between postoperative and 1-month follow-up DCE-MR imaging is also shown (r = −0.10, P = .78) (C).
Tables
Descriptive No. (%) Age groups (per patient, n = 27) (yr) 50 and younger 3 (11.1) 51–64 12 (44.4) 65–74 9 (33.3) 75 or older 3 (11.1) Sex (per patient, n = 27) Female 16 (59.2) Male 11 (40.7) Histology (per patient, n = 27) Breast 9 Adenocarcinoma 5 NSCLC 5 RCC 3 Colon 2 Sarcoma 1 SCC 1 Small-cell carcinoma 1 Median KPS (per treatment, n = 33) Pre 90 Post 90 1 Month 90 Median PFS (per treatment, n = 33) (days) 137 Deceased (per patient, n = 27) 3 (11.1) Prior SRS (per treatment, n = 33) 25 (75.8) Completely ablated (per treatment, n = 33) 17 (51.5) Posttreatment enhancement on postoperative imaging (n = 20) 16 (80) Preoperative DCE-MRI available (per treatment, n = 33) 33 (100) Postoperative DCE-MRI available (per treatment, n = 33) 20 (60.6) One-month DCE-MRI available (per treatment, n = 33) 25 (75.7) Local recurrence (per treatment, n = 33) 14 (42.4) Post-LITT chemotherapy (per treatment, n = 33) 16 (48.5) Note:—NSCLC indicates non-small-cell lung cancer; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; KPS, Karnofsky performance scale; SRS, stereotactic radiosurgery.
Predicted Reference Short-PFS Long-PFS Short-PFS 7 1 Long-PFS 0 3 Note:—Short-PFS indicates time to local recurrence of <6 months; Long-PFS, time to local recurrence of >6 months.
Jump to section
Related Articles
Cited By...
- No citing articles found.